Stock 1530 3SBIO INC.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages 3SBio Inc.

Equities

1530

KYG8875G1029

Market Closed - Hong Kong S.E.
Other stock markets
 01:38:42 28/06/2024 pm IST 		5-day change 1st Jan Change
6.44 HKD +2.71% Intraday chart for 3SBio Inc. +6.10% -14.36%
25/06 3Sbio Inc. Declares Final Dividend for the Year Ended 31 December 2023, Payable on 5 August 2024 CI
25/06 3Sbio Inc. Announces Board Changes CI

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
3Sbio Inc. Declares Final Dividend for the Year Ended 31 December 2023, Payable on 5 August 2024
3Sbio Inc. Announces Board Changes
3SBIO Unit to Cooperate on Development, Sale of Weight Management Injection
3Sbio Inc. Announces Board and Committee Changes
3SBio Inc. Approves Recombinant Human Thrombopoietin Injection for Pediatric ITP Indication
3SBio Inc. commences an Equity Buyback for 243,892,041 shares, representing 10% of its issued share capital, under the authorization approved on June 20, 2023.
3SBio's 2023 Profit Falls 19%, EPS Misses Estimates
3SBio Inc. Proposes Final Dividend for the Year Ended 31 December 2023, Payable on August 05, 2024
3SBio Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
China's NMPA Gives 3SBio Permission to Sell Anti-Dandruff Product
Mandi Foam of 3SBio Inc. Approves for Market Launch
3SBio Secures Exclusive License to CStone's Anti-Tumor Drug in China
3SBio's H1 Attributable Profit Rises, Beats EPS Estimates
3SBio Inc. Reports Earnings Results for the Half Year Ended June 30, 2023
3SBio Hires Former JPMorgan Exec as CFO
3SBio Rolls Out Pruritus Medication in China
3SBio Inc. Announces Narfuraphine Hydrochloride Orally Disintegrating Tablets Co-Developed by 3Sbio Inc. and Toray in Japan Approved for Launch in the Market
3SBio Enrolls First Patient in Phase 3 Trial of Thrombocytopenia Treatment
3SBio Inc. Proposes Final Dividend for the Year Ended 31 December 2022, Payable on 11 July 2023
3SBio Inc. Announces First Patient Enrolled in the Trial of Phase III Clinical Study of Recombinant Human Thrombopoietin Injection
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. 1530 Stock
  4. News 3SBio Inc.
  5. Other languages